Zobrazeno 1 - 10
of 631
pro vyhledávání: '"Vicente Valero"'
Autor:
Rania M. Mohamed, Bikash Panthi, Beatriz E. Adrada, Medine Boge, Rosalind P. Candelaria, Huiqin Chen, Mary S. Guirguis, Kelly K. Hunt, Lei Huo, Ken-Pin Hwang, Anil Korkut, Jennifer K. Litton, Tanya W. Moseley, Sanaz Pashapoor, Miral M. Patel, Brandy Reed, Marion E. Scoggins, Jong Bum Son, Alastair Thompson, Debu Tripathy, Vicente Valero, Peng Wei, Jason White, Gary J. Whitman, Zhan Xu, Wei Yang, Clinton Yam, Jingfei Ma, Gaiane M. Rauch
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Triple-negative breast cancer (TNBC) is often treated with neoadjuvant systemic therapy (NAST). We investigated if radiomic models based on multiparametric Magnetic Resonance Imaging (MRI) obtained early during NAST predict pathologic comple
Externí odkaz:
https://doaj.org/article/6a9d5085faa94e07a2d7d1b1c2688f40
Autor:
Enrique Soto-Pérez-de-Celis, Dione Aguilar-y-Méndez, Silvia R. Allende-Pérez, Rosa Ma. Álvarez-Gómez, Verónica Cedillo-Compeán, Ma. Teresa de J. Cervantes-Díaz, Mariana Chávez-MacGregor, Mabelid Mabiani-Céspedes, Edith A. Monreal-Carrillo, Ma. Paulina Núñez-Martínez, Guadalupe E. Paredes-Rivera, Edith Rojas-Castillo, Sofía Saba-Cohén, Isabelle A. Timeus-Salvato, Emma L. Verastegui-Avilés, Silvia Vidal-Millán, Talia Wegman-Ostrosky, Claudia Arce-Salinas, Juan E. Bargalló-Rocha, Verónica Bautista-Piña, Guadalupe Cervantes-Sánchez, Christian H. Flores-Balcázar, Ma. del Carmen Lara-Tamburrino, Ana Lluch-Hernández, Antonio Maffuz-Aziz, Víctor M. Pérez-Sánchez, Adela Poitevin-Chacón, Efraín Salas-González, Laura Torrecillas-Torres, Vicente Valero-Castillo, Yolanda Villaseñor-Navarro, Jesús Cárdenas-Sánchez
Publikováno v:
Gaceta Mexicana de Oncología, Vol 23, Iss 3 (2024)
El cáncer mamario impacta en diversas esferas de la vida del paciente y su entorno familiar y social. Se trata de una enfermedad compleja que requiere un abordaje multidisciplinario tanto para el diagnóstico como para el tratamiento, así como en l
Externí odkaz:
https://doaj.org/article/640c35456c5c41e08568b6fdb27c3e18
Autor:
Guadalupe Cervantes-Sánchez, Tania Hernández-Barragán, Fernando Aldaco-Sarvide, Claudia Arce-Salinas, Juan E. Bargalló-Rocha, Verónica Bautista-Piña, Mariana Chávez-MacGregor, Georgina Garnica-Jaliffe, Christian H. Flores-Balcázar, Ma. del Carmen Lara-Tamburrino, Ana Lluch-Hernández, Antonio Maffuz-Aziz, Perla Pérez, Víctor M. Pérez-Sánchez, Adela Poitevin-Chacón, Efraín Salas-González, Enrique Soto-Pérez-de-Celis, Laura Torrecillas-Torres, Vicente Valero-Castillo, Yolanda Villaseñor-Navarro, Jesús Cárdenas-Sánchez
Publikováno v:
Gaceta Mexicana de Oncología, Vol 23, Iss 2 (2024)
El cáncer de mama es la neoplasia más frecuente y con mayor mortalidad en mujeres en todo el mundo. La décima actualización del Consenso Mexicano Sobre Diagnóstico y Tratamiento del Cáncer Mamario (2023) es publicada por sus autores en diferent
Externí odkaz:
https://doaj.org/article/24c741c968fb47c599993c71f1ed2804
Autor:
Fatma Nihan Akkoc Mustafayev, Diane D. Liu, Angelica M. Gutierrez, John E. Lewis, Nuhad K. Ibrahim, Vicente Valero, Daniel J. Booser, Jennifer K. Litton, Kimberly Koenig, Dihua Yu, Nour Sneige, Banu K. Arun
Publikováno v:
European Journal of Breast Health, Vol 19, Iss 4, Pp 267-273 (2023)
Objective:Risk-reducing therapy with selective estrogen receptor (ER) modulators and aromatase inhibitors reduce breast cancer risk. However, the effects are limited to ER-positive breast cancer. Therefore, new agents with improved toxicity profiles
Externí odkaz:
https://doaj.org/article/007df5a2dfff4116b58ca4a6c94fbe74
Autor:
Juan E. Bargalló-Rocha, Sergio Aguilar-Villanueva, Carolina Ahumada-Pámanes, Claudia Arce-Salinas, Alethia Álvarez-Cano, Isaac Baley-Spindel, Verónica Bautista-Piña, Guadalupe Cervantes-Sánchez, Mariana Chávez-MacGregor, Nererida Esparza-Arias, Johnatan Figueroa-Padilla, Christian H. Flores-Balcázar, Sonia Ma. Flores-Moreno, Antonio Maffuz-Aziz, Federico Maldonado-Magos, Ma. del Carmen Lara-Tamburrino, Ana Lluch-Hernández, Sarina Navarro-Santiesteban, Víctor M. Pérez-Sánchez, Adela Poitevin-Chacón, Eva Ruvalcaba-Limón, Efraín Salas-González, Amelia Sarricolea-Puch, Enrique Soto-Pérez-de-Celis, Laura Torrecillas-Torres, Vicente Valero-Castillo, Yolanda Villaseñor-Navarro, Jesús Cárdenas-Sánchez
Publikováno v:
Gaceta Mexicana de Oncología, Vol 23, Iss 1 (2024)
El cáncer mamario en estadios tempranos tiene un manejo local (quirúrgico y radioterapia) y sistémico específico. Este tipo de cáncer incluye el carcinoma ductal in situ y los cánceres de mama en estadios I, IIA, IIB y IIIA. Esta décima actual
Externí odkaz:
https://doaj.org/article/dfeaa7c5944c493bbee614ad9fa10d7b
Autor:
Bikash Panthi, Rania M. Mohamed, Beatriz E. Adrada, Medine Boge, Rosalind P. Candelaria, Huiqin Chen, Kelly K. Hunt, Lei Huo, Ken-Pin Hwang, Anil Korkut, Deanna L. Lane, Huong C. Le-Petross, Jessica W. T. Leung, Jennifer K. Litton, Sanaz Pashapoor, Frances Perez, Jong Bum Son, Jia Sun, Alastair Thompson, Debu Tripathy, Vicente Valero, Peng Wei, Jason White, Zhan Xu, Wei Yang, Zijian Zhou, Clinton Yam, Gaiane M. Rauch, Jingfei Ma
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Early prediction of neoadjuvant systemic therapy (NAST) response for triple-negative breast cancer (TNBC) patients could help oncologists select individualized treatment and avoid toxic effects associated with ineffective therapy in patients unlikely
Externí odkaz:
https://doaj.org/article/ce05b7a736b747c6b99c4058b0f5d015
Autor:
Zijian Zhou, Beatriz E. Adrada, Rosalind P. Candelaria, Nabil A. Elshafeey, Medine Boge, Rania M. Mohamed, Sanaz Pashapoor, Jia Sun, Zhan Xu, Bikash Panthi, Jong Bum Son, Mary S. Guirguis, Miral M. Patel, Gary J. Whitman, Tanya W. Moseley, Marion E. Scoggins, Jason B. White, Jennifer K. Litton, Vicente Valero, Kelly K. Hunt, Debu Tripathy, Wei Yang, Peng Wei, Clinton Yam, Mark D. Pagel, Gaiane M. Rauch, Jingfei Ma
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Neoadjuvant systemic therapy (NAST) followed by surgery are currently standard of care for TNBC with 50-60% of patients achieving pathologic complete response (p
Externí odkaz:
https://doaj.org/article/9d1afc4d0a46451ea11ba6d0e3bea0a2
Autor:
Tal Sella, Yue Zheng, Nabihah Tayob, Kathryn J. Ruddy, Rachel A. Freedman, Chau Dang, Denise Yardley, Steven J. Isakoff, Vicente Valero, Michelle DeMeo, Harold J. Burstein, Eric P. Winer, Antonio C. Wolff, Ian Krop, Ann H. Partridge, Sara M. Tolaney
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-9 (2022)
Abstract In the ATEMPT trial, adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel plus trastuzumab (TH) for stage I HER2-positive breast cancer improved patient-reported outcomes (PROs), while maintaining excellent disease outcomes. We repo
Externí odkaz:
https://doaj.org/article/db47278c15ae47048316e04bc579a690
Autor:
Hui Chen, Qingqing Ding, Laila Khazai, Li Zhao, Senthil Damodaran, Jennifer K. Litton, Gaiane M. Rauch, Clinton Yam, Jeffrey T. Chang, Sahil Seth, Bora Lim, Alastair M. Thompson, Elizabeth A. Mittendorf, Beatriz Adrada, Kiran Virani, Jason B. White, Elizabeth Ravenberg, Xingzhi Song, Rosalind Candelaria, Banu Arun, Naoto T. Ueno, Lumarie Santiago, Sadia Saleem, Sausan Abouharb, Rashmi K. Murthy, Nuhad Ibrahim, Mark J. Routbort, Aysegul Sahin, Vicente Valero, William Fraser Symmans, Debu Tripathy, Wei-Lien Wang, Stacy Moulder, Lei Huo
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Recent advances have been made in targeting the phosphoinositide 3-kinase pathway in breast cancer. Phosphatase and tensin homolog (PTEN) is a key component of that pathway. Objective: To understand the changes in PTEN expression over the
Externí odkaz:
https://doaj.org/article/d6308ee798424003bf82ce6d0277871d
Autor:
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani Hu, Douglas Weckstein, Antonio C. Wolff, Katherine Reeder-Hayes, Hope S. Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Schneider, Audrey Merrill Garrett, Kelly Marcom, Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta Liu, Kathryn J. Ruddy, Yue Zheng, Shoshana M. Rosenberg, Richard D. Gelber, Lorenzo Trippa, William Barry, Michelle DeMeo, Harold Burstein, Ann Partridge, Eric P. Winer, Ian Krop, Sara M. Tolaney
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract The excellent outcomes seen in patients treated with adjuvant trastuzumab emtansine (T-DM1) in the ATEMPT trial and the favorable toxicity profile associated with this agent make T-DM1 a potential therapeutic option for select patients with
Externí odkaz:
https://doaj.org/article/e88fcc1488804534afd42026e28dc869